T. Jones

发表

Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide.

K. Jansen, S. Hoiseth, E. Murphy, 2009, Vaccine.

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.

E. Emini, A. Gurtman, W. Gruber, 2013, Vaccine.

AB0440 CHANGES IN KEY LABORATORY VALUES WITH TOFACITINIB 5 MG BID TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS AND RHEUMATOID ARTHRITIS

G. Burmester, O. FitzGerald, P. Nash, 2019, Abstracts Accepted for Publication.

A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults.

John L. Perez, K. Jansen, H. Marshall, 2013, Vaccine.

A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial.

W. Gruber, H. Marshall, S. Lambert, 2012, Vaccine.

Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.

John L. Perez, K. Jansen, H. Marshall, 2012, The Lancet. Infectious diseases.

Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France.

John L. Perez, K. Jansen, P. Liberator, 2017, Vaccine.

Meningococcal serogroup B vaccines: Estimating breadth of coverage

John L. Perez, K. Jansen, P. Liberator, 2016, Human vaccines & immunotherapeutics.

Immunogenicity, Tolerability and Safety in Adolescents of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered with Quadrivalent Human Papilloma Virus Vaccine

J. Absalon, John L. Perez, K. Jansen, 2016, The Pediatric infectious disease journal.

Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 Meningococcal Group B Vaccine Administered Concomitantly With Diphtheria, Tetanus, and Acellular Pertussis and Inactivated Poliomyelitis Vaccines to Healthy Adolescents

John L. Perez, K. Jansen, T. Vesikari, 2016, Journal of the Pediatric Infectious Diseases Society.

Immunogenicity and Reactogenicity of a 13-Valent-pneumococcal Conjugate Vaccine Administered at 2, 4, and 12 Months of Age: A Double-blind Randomized Active-controlled Trial

E. Emini, W. Gruber, Ly-Mee Yu, 2010, The Pediatric infectious disease journal.

MenB-FHbp Vaccine Protects Against Diverse Meningococcal Strains in Adolescents and Young Adults: Post Hoc Analysis of Two Phase 3 Studies

J. Absalon, John L. Perez, R. O'neill, 2020, Infectious Diseases and Therapy.

The bivalent factor H binding protein meningococcal serogroup B vaccine elicits bactericidal antibodies against representative non-serogroup B meningococci.

J. Absalon, P. Liberator, A. Anderson, 2018, Vaccine.

A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults

J. Absalon, John L. Perez, K. Jansen, 2017, The New England journal of medicine.

Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine

K. Jansen, A. Gribenko, D. Caugant, 2018, mBio.

A Randomized Clinical Trial of the Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine Compared to 23-Valent Polysaccharide Vaccine in Frail, Hospitalized Elderly

C. Macintyre, A. Hayen, R. Lindley, 2014, PloS one.

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine.

E. Emini, A. Gurtman, R. Frenck, 2015, Vaccine.

Neisseria meningitidis Serogroup B Vaccine, Bivalent rLP2086, Induces Broad Serum Bactericidal Activity Against Diverse Invasive Disease Strains Including Outbreak Strains

John L. Perez, K. Jansen, R. O'neill, 2017, The Pediatric infectious disease journal.

Phase 3 trial evaluating the immunogenicity, safety, and tolerability of manufacturing scale 13-valent pneumococcal conjugate vaccine.

E. Emini, W. Gruber, R. Konior, 2011, Vaccine.

Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents.

J. Absalon, John L. Perez, K. Jansen, 2019, Vaccine.

Immunogenicity, safety, and tolerability of the meningococcal serogroup B bivalent rLP2086 vaccine in adult laboratory workers.

John L. Perez, K. Jansen, R. O'neill, 2016, Vaccine.

Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial.

John L. Perez, K. Jansen, H. Marshall, 2017, The Lancet. Infectious diseases.

Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared to Those of a 7-Valent Pneumococcal Conjugate Vaccine Given as a Three-Dose Series with Routine Vaccines in Healthy Infants and Toddlers

John Z. Liang, A. Razmpour, E. Emini, 2010, Clinical and Vaccine Immunology.

1081Immunogenicity of Human Papilloma Vaccine Coadministered with an Investigational Bivalent rLP2086 Vaccine Against Meningococcal Serogroup B in Healthy Adolescents

John L. Perez, K. Jansen, J. Eiden, 2014 .

Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents

Robert E. O'Neill, Kathrin U. Jansen, Jacek Wysocki, 2015, Journal of the Pediatric Infectious Diseases Society.

Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease.

Roger French, Ellen Murphy, Michelle Mack, 2010, Vaccine.

Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults

A. Gurtman, W. Gruber, M. van Cleeff, 2019, Human vaccines & immunotherapeutics.

From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine

J. Absalon, John L. Perez, K. Jansen, 2018, Expert review of vaccines.

Selection of diverse strains to assess broad coverage of the bivalent FHbp meningococcal B vaccine

John L. Perez, K. Jansen, A. Anderson, 2020, npj Vaccines.

Safety signal detection and evaluation in clinical development programs: A case study of tofacitinib

H. Valdez, R. Rojo, Ann M. Madsen, 2017, Pharmacology research & perspectives.

Serious infection with tofacitinib in patients with rheumatoid arthritis: the importance of context

J. Rivas, C. Connell, T. Jones, 2020 .

Potential impact of the bivalent rLP2086 vaccine on Neisseria meningitidis carriage and invasive serogroup B disease

John L. Perez, K. Jansen, A. Anderson, 2012, Human vaccines & immunotherapeutics.

Selection of diverse strains to assess broad coverage of the bivalent FHbp meningococcal B vaccine

John L. Perez, K. Jansen, A. Anderson, 2020, npj Vaccines.

A Randomized, Controlled, Phase 1/2 Trial of a Neisseria meningitidis Serogroup B Bivalent rLP2086 Vaccine in Healthy Children and Adolescents

John L. Perez, K. Jansen, H. Marshall, 2013, The Pediatric infectious disease journal.

Safety and Immunogenicity of a Meningococcal B Bivalent rLP2086 Vaccine in Healthy Toddlers Aged 18–36 Months: A Phase 1 Randomized-controlled Clinical Trial

Kathrin U. Jansen, Shannon L. Harris, J. Ziegler, 2012, The Pediatric infectious disease journal.

Immunogenicity and Reactogenicity of a 13-Valent-pneumococcal Conjugate Vaccine Administered at 2, 4, and 12 Months of Age

E. Emini, W. Gruber, S. Faust, 2010 .